Health · Healthcare & Policy · 6 hrs ago
FDA authorizes Theraclion’s noninvasive device for treating vein reflux
The FDA authorized Theraclion’s Sonovein device to treat superficial venous reflux in the great saphenous vein, a major cause of varicose veins.
The device uses focused ultrasound and treats veins without incisions or catheters.
Varicose veins affect about one third of adults, according to the information provided.
In a trial of 70 people at four sites in the US and Europe, 96.8% of treated veins were closed after one year.
The study reported no serious or unexpected adverse events and one mild event.
The authorization gives US patients and doctors access to a noninvasive treatment option for this condition.
Theraclion plans to set up treatment centers and provide physician training and support, while working toward insurance coverage.
The FDA granted De Novo authorization for Theraclion’s Sonovein device to treat superficial venous reflux in great saphenous veins.
Sonovein is described as the first noninvasive focused ultrasound platform for treating varicose veins.
The FDA’s decision was based on the VEINRESET pivotal trial, which reported a 96.8% vein occlusion rate after one year.
The trial reported no serious or unanticipated adverse events and one mild adverse event.
Theraclion plans to establish US treatment centers and provide physician training and support.
- Who
- Theraclion received authorization for its Sonovein device from the US Food and Drug Administration.
- What
- The FDA granted De Novo authorization for Sonovein to treat superficial venous reflux in great saphenous veins.
- When
- The authorization was announced on November 16, 2026.
- Where
- The United States. The trial enrolled participants at sites in the US and Europe.
- Why
- The FDA’s ruling was based on results from the VEINRESET pivotal clinical trial.
This story does not have two clearly opposing sides.
The pivotal trial enrolled 70 participants across four sites in the US and Europe and met its primary endpoint, with a 96.8% great saphenous vein occlusion rate after one year.
Theraclion announced that the FDA had granted De Novo authorization for Sonovein.
- Device
- Sonovein
- FDA decision
- De Novo authorization
- Trial
- VEINRESET (NCT05926830)
- Trial participants
- 70
- One-year vein occlusion rate
- 96.8%
- Reported adverse events
- No serious or unanticipated events; one mild event
What people are saying
This authorization marks the culmination of years of clinical and regulatory work and opens a defining new chapter for Theraclion. Sonovein enables entirely noninvasive vein treatment, without incisions or catheters. We are proud to bring this fundamental advance to US patients and physicians. I thank our teams, clinical investigators, partners, and shareholders, whose dedication and belief in our vision helped make this achievement possible. We also thank the FDA for its constructive engagement throughout the review process.